| Metric | Value |
| Company Name | ADMA Biologics, Inc. |
| Exchange & Ticker | Nasdaq: ADMA |
| Date Founded | June 24, 2004 |
| State of Incorporation | Delaware |
| Headquarters | 465 State Route 17, Ramsey, NJ 07446 |
| Manufacturing Campus | 5800 Park of Commerce Blvd, Boca Raton, FL |
| President & CEO | Adam S. Grossman |
| Chief Financial Officer | Brad Tade |
| Total Employees | 647 (including 7 part-time) |
| Fiscal 2025 Total Revenue | $510.17 million |
| Fiscal 2025 GAAP Net Income | $146.93 million |
| Fiscal 2025 Adjusted EBITDA | $231.0 million |
| Fiscal 2025 ASCENIV Revenue | $363.0 million |
| Shares Outstanding | 238,159,176 |
| Peak Annual Processing Capacity | Up to 600,000 liters |
| Number of FDA-Licensed Plasma Centers | 10 (Divesting 3 in Q1 2026) |
| Projected 2026 Revenue | >$635.0 million |
| Projected 2027 Revenue | >$775.0 million |
| Projected 2029 Revenue | >$1.1 billion |
| Key Commercial Products | ASCENIV, BIVIGAM, Nabi-HB |
Company Overview
ADMA Biologics, Inc. is a heavily integrated, end-to-end commercial biopharmaceutical enterprise focused squarely on the immunology and infectious disease markets. The organization manufactures, markets, and develops specialty plasma-derived biologics. These specialized therapeutics are engineered for the treatment of immunodeficient patients who face severe risks from infection, as well as individuals suffering from targeted infectious diseases. The primary patient populations consist of naturally immune-compromised individuals suffering from underlying immune deficiency disorders, as well as those who are medically immune-suppressed.
With an overarching strategy geared toward controlling the entire production life cycle, ADMA Biologics operates one of the few vertically integrated plasma product manufacturing networks in the United States. The operational footprint is anchored by an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, which commands a peak annual processing capability of up to 600,000 liters.
The organization’s commercial success is driven by an approved portfolio consisting of three major biologic therapeutics: ASCENIV, BIVIGAM, and Nabi-HB. These products are derived from human blood plasma and are engineered utilizing complex Cohn fractionation methods, sophisticated viral inactivation processes, and patented microneutralization assays. Through strict adherence to the latest current Good Manufacturing Practices (cGMP) and proactive implementation of artificial intelligence in its supply chain, the enterprise has accelerated production timelines, driven unparalleled yield enhancements, and established a durable, highly profitable commercial profile. The enterprise projects robust growth metrics, anticipating total annual revenues to surpass the $1.1 billion mark by fiscal year 2029, a reflection of the deep clinical differentiation of its portfolio and expanding footprint across the specialty biologics landscape.
Business Segments
ADMA Biologics organizes its financial and operational footprint into two primary business segments: ADMA BioManufacturing and Plasma Collection Centers.
ADMA BioManufacturing
- Segment Revenue (2025): $493.00 million
- Percentage of Total Revenue: 96.63%
The ADMA BioManufacturing segment represents the core operational engine of the enterprise. This division handles the intricate processes of plasma fractionation, purification, formulating, filling, packaging, testing, and distributing the final therapeutic products. Operations are primarily centered at the Boca Raton facility. The division is responsible for generating revenue through the direct commercial sale of ASCENIV, BIVIGAM, and Nabi-HB, alongside the sale of intermediate products and contract manufacturing services provided to third-party clients.
The scope of this segment also encompasses significant supply-chain enhancements, including a fully authorized in-house aseptic filling machine and a highly sophisticated 4,400-liter expanded plasma pool production scale. Recent FDA approvals for a yield enhancement production process have profoundly benefited this segment, yielding approximately 20% more product from the exact same starting volume of raw source plasma. This capability is expected to drastically expand margins and secure robust cash flow generation.
Plasma Collection Centers (ADMA BioCenters)
- Segment Revenue (2025): $17.03 million
- Percentage of Total Revenue: 3.34%
The Plasma Collection Centers segment functions as the vital raw material procurement division. Operating strictly under FDA licensure, these centers execute the collection of normal source plasma and high-titer hyperimmune plasma through an automated plasmapheresis process. While a significant portion of the collected plasma is utilized internally by the ADMA BioManufacturing segment to produce commercial therapeutics, excess plasma inventory is sold on the open spot market or via supply agreements to third parties, generating direct external revenue.
A typical center processes between 30,000 to 50,000 liters of source plasma annually. At the close of 2025, the segment managed ten facilities primarily located in the southeastern United States. In a strategic pivot toward a more flexible, capital-efficient supply model, three of these centers were marked for divestiture in late 2025 for a collective $12.0 million purchase price, while retaining long-term supply agreements with the purchaser to ensure raw material flow.
(Note: An additional 0.03% of total revenue, equating to $0.14 million, is derived from License Revenue).
History and Evolution
The enterprise was originally incorporated in the State of New Jersey on June 24, 2004, under the vision of targeting niche immune-compromised patient populations with unmet medical needs. Recognizing the strategic advantages of broader corporate flexibility, the entity re-incorporated in Delaware on July 16, 2007.
Early operations focused on the extensive research, development, and complex clinical trials required to bring a specialized respiratory syncytial virus (RSV) hyperimmune globulin to market. By 2013, the organization successfully executed an initial public offering to raise necessary capital.
The most transformative evolutionary phase occurred in 2017. In June of that year, the enterprise aggressively shifted from a research-heavy entity to an end-to-end commercial manufacturer by executing an asset acquisition of the Biotest Therapy Business Unit. This acquisition transferred ownership of the Boca Raton manufacturing facility and the rights to BIVIGAM and Nabi-HB directly into the corporate portfolio.
Following the acquisition, a comprehensive overhaul of site-wide quality and compliance functions was implemented. This massive integration paid dividends rapidly:
- Q3 2017: Resumed production of Nabi-HB, with the first commercial batch released in early 2018.
- Q4 2017: Resumed production of BIVIGAM.
- April 2019: Secured FDA approval for ASCENIV.
- May 2019: Secured FDA approval for the BIVIGAM Prior Approval Supplement, allowing a full commercial relaunch.
- August & October 2019: Successfully launched first commercial sales of BIVIGAM and ASCENIV, respectively.
In 2021, the operational scale leaped forward with the FDA approval of a 4,400-liter plasma pool process for BIVIGAM and in-house fill-finish capabilities, cementing the independence of the supply chain. In 2024, the enterprise launched “ADMAlytics,” a sophisticated artificial intelligence tool designed to prospectively automate and optimize plasma pooling and operational efficiencies. By 2025, the corporate evolution reached a massive inflection point with the FDA clearance of an industry-leading yield enhancement production process, driving a 20% increase in IG production yields without requiring additional raw plasma.
Products and Services
The corporate portfolio focuses exclusively on high-value, plasma-derived biologics containing polyclonal antibodies that confer passive immunization.
ASCENIV (Immune Globulin Intravenous, Human-slra 10% Liquid)
- Product Revenue (2025): $363.0 million
- Percentage of Total Revenue: 71.15%
ASCENIV represents the commercial crown jewel of the enterprise. Approved in April 2019, it is an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI), also known as Primary Immunodeficiency Disease (PIDD), in adults and adolescents. ASCENIV is profoundly differentiated by its patented manufacturing methodology. The production utilizes a tailored pooling design that blends normal source plasma with plasma from donors rigorously tested using a proprietary microneutralization assay. This ensures the final therapeutic contains standardized, elevated neutralizing antibody titers to Respiratory Syncytial Virus (RSV) alongside broad-spectrum protection against other pathogens like S. pneumoniae, H. influenza type B, and cytomegalovirus (CMV).
- Clinical Impact: In pivotal Phase 3 trials, ASCENIV met its primary endpoint with zero Serious Bacterial Infections (SBIs) reported over a 12-month treatment period.
- Production: Manufactured efficiently at the 4,400-liter scale.
- Regulatory Momentum: A supplemental Biologics License Application (sBLA) was filed in June 2025 to expand the label to include pediatric patients aged two years and older.
BIVIGAM
- Percentage of Total Revenue: Classified alongside general IG revenues and subject to market demand dynamics.
BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin G (IgG) antibodies. It is indicated for the treatment of PI in adults and pediatric patients two years of age and older. BIVIGAM contains a broad range of antibodies naturally present in human plasma, offering critical protection against a variety of bacterial and viral infections for patients suffering from genetic disorders such as X-linked agammaglobulinemia and severe combined immunodeficiency.
- Scale: Manufactured utilizing the FDA-approved 4,400-liter plasma pool process, maximizing margin profiles and minimizing required labor hours.
- Label Expansion: The FDA successfully approved the expansion of the BIVIGAM label in December 2023 to include pediatric patients two years of age and older.
Nabi-HB (Hepatitis B Immune Globulin, Human)
- Percentage of Total Revenue: Historically represents less than 10% of ADMA BioManufacturing revenue (reported within intermediates/other products).
Nabi-HB is a specialized hyperimmune globulin rich in targeted antibodies to the Hepatitis B virus. It is utilized to treat acute exposure to blood containing HBsAg, perinatal exposure in infants born to HBsAg-positive mothers, and sexual or household exposure to the virus. Nabi-HB is formulated from plasma donors heavily vaccinated against Hepatitis B and has an impeccable track record of long-term safety since its initial market introduction in 1999.
Contract Manufacturing and Intermediates
The enterprise leverages its world-class cGMP infrastructure to offer specialized Contract Development and Manufacturing Organization (CDMO) services. This includes aseptic filling, labeling, packaging, and unique GMP testing protocols for third-party clients. Furthermore, the intermediate protein fractions extracted during the Cohn cold ethanol fractionation process are sold externally.
Brand Portfolio
The corporate brand identity is fiercely protected and recognized globally across the biopharmaceutical and immunological spaces. The brand portfolio drives the specific commercial identity of each therapeutic.
ASCENIV™
- Percentage of Total Revenue: 71.15% ($363.0 million) The flagship therapeutic brand. ASCENIV acts as the primary growth engine, commanding premium market positioning due to its highly specialized hyperimmune properties combined with standard IVIG capabilities.
BIVIGAM®
A cornerstone brand in the traditional IVIG landscape. It is recognized by clinicians and payers as a highly reliable, pure, and efficacious therapy for standard PI and PIDD treatments across both adult and pediatric populations.
Nabi-HB®
A legacy brand in the post-exposure prophylactic market for Hepatitis B. Recognized universally by hospital pharmacies and emergency departments for immediate intervention protocols.
ADMAlytics
While not a therapeutic product, ADMAlytics is a highly visible operational brand. It represents the proprietary artificial intelligence and machine learning software implemented across supply chain, production, and commercial divisions. It is recognized as the technological edge that reduces personnel hours, streamlines plasma pooling, and predicts 7-to-12-month manufacturing outcomes with extreme precision.
Geographical Presence
The corporate footprint is predominantly concentrated within the United States, which serves as the primary hub for collection, manufacturing, and commercial distribution.
United States
- Region Revenue (2025): $504.07 million
- Percentage of Total Revenue: 98.80%
- Footprint: * Ramsey, New Jersey: Corporate Headquarters handling executive administration, medical affairs, and centralized financial operations.
- Boca Raton, Florida (Main Campus): A sprawling 600,000-liter capacity FDA-licensed plasma fractionation and purification facility.
- Boca Raton, Florida (Expansion Campus): Newly acquired real estate ($12.6 million investment in July 2025) designated for production expansion, ambient storage, and cold-chain infrastructure redundancies.
- Southeastern U.S.: Network of FDA-licensed plasma collection centers operating under the ADMA BioCenters subsidiary.
International Markets
- Region Revenue (2025): $6.11 million
- Percentage of Total Revenue: 1.20%
- Footprint: The enterprise generates targeted international revenue via specialized licensing and export agreements. Notably, an exclusive agreement exists with Biotest AG to market and sell ASCENIV in Europe, Northern Africa, and the Middle East. Furthermore, specific plasma collection centers hold active approvals from the South Korean Ministry of Food and Drug Safety (MFDS) for international distribution.
Profit and Loss
The fiscal momentum of the enterprise highlights a rapid trajectory of revenue expansion and aggressive cost-control measures driving immense profitability.
| Financial Metric | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
| Total Revenues | $510,173,000 | $426,454,000 | $258,072,000 |
| Cost of Product Revenue | $217,390,000 | $206,901,000 | $169,273,000 |
| Gross Profit | $292,783,000 | $219,553,000 | $88,799,000 |
| Depreciation & Amortization | $8,096,000 | $8,045,000 | $8,332,000 |
| Stock-Based Compensation | $20,026,000 | $13,616,000 | $6,187,000 |
| Income (Loss) Before Taxes | $182,656,000 | $125,714,000 | $(28,239,000) |
| Deferred Income Tax Provision | $11,020,000 | $(84,280,000) | $0 |
| GAAP Net Income (Loss) | $146,930,000 | $197,673,000 | $(28,239,000) |
| Adjusted EBITDA | $231,000,000 | $235,000,000 (Guidance) | N/A |
| Adjusted Net Income | $161,000,000 | N/A | N/A |
Financial Context: The 20% surge in total revenues from 2024 to 2025 was dominantly propelled by ASCENIV, which achieved $363.0 million in standalone revenue (a 51% year-over-year growth rate). The massive expansion in Gross Profit is a direct result of the FDA-approved yield enhancement processes that dramatically lowered the cost-per-gram of IG produced.
Balance Sheet
The liquidity and structural financial health of the enterprise have fortified considerably, allowing aggressive capital deployment and debt reduction.
| Balance Sheet Metric | Year Ended December 31, 2025 |
| Cash and Cash Equivalents | $88,000,000 |
| Property & Equipment (Gross) | $103,405,000 |
| Accumulated Depreciation | $(38,348,000) |
| Property & Equipment (Net) | $65,057,000 |
| Goodwill | $3,500,000 |
| Total Debt (JPM Term Loan) | $74,063,000 |
| Debt Discount & Issuance Costs | $(1,920,000) |
| Net Notes Payable | $72,143,000 |
| Accrued Distribution Fees | $14,808,000 |
| Income Taxes Payable | $8,616,000 |
| Accrued Rebates | $5,758,000 |
| Accrued Incentives | $6,005,000 |
| Total Accrued Expenses & Current Liabilities | $40,466,000 |
Financial Context: In August 2025, the enterprise executed a major financial restructuring by closing a $300.0 million senior secured credit facility with JPMorgan Chase Bank, N.A. This consisted of a $75.0 million term loan and a highly flexible $225.0 million revolving credit facility (undrawn at closing). This eliminated previous higher-cost Ares term loans and revolutionized the corporate liquidity profile.
Cash Flow
Cash flow generation indicates heavy operating leverage and robust internal funding for ongoing capital expenditure and share repurchases.
| Cash Flow Metric | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
| Net Income (Loss) | $146,930,000 | $197,673,000 | $(28,239,000) |
| Depreciation & Amortization | $8,096,000 | $8,045,000 | $8,332,000 |
| Deferred Income Tax Provision | $11,020,000 | $(84,280,000) | $0 |
| Stock-Based Compensation | $20,026,000 | $13,616,000 | $6,187,000 |
| Loss on Extinguishment of Debt | $3,336,000 | $1,243,000 | $26,174,000 |
| Cash Paid for Interest | $9,078,000 | $10,668,000 | $18,051,000 |
| Cash Paid for Income Taxes | $19,683,000 | $9,392,000 | $0 |
Financial Context: The transition from a cash-burn operation in 2023 to immense cash generation in 2025 provided the financial firepower to authorize a colossal $200.0 million Total Share Repurchase Initiative.
Board of Directors and Leadership Team
The management syndicate blends decades of highly specialized blood and plasma industry expertise with rigorous capital markets acumen.
- Adam S. Grossman (Founder, Director, President, & Chief Executive Officer): The driving force behind the corporate mission since 2004. Adam Grossman possesses over 30 years of specialized experience in the blood and plasma industry. Under his stewardship, the enterprise executed a successful IPO, completed over $1.5 billion in capital market transactions, and acquired the massive Biotest asset footprint. He directly engineered the regulatory framework that achieved FDA approvals for ASCENIV and BIVIGAM and holds multiple patents critical to the proprietary manufacturing process. He also serves as the Chair of the North America Board of Directors of the Plasma Protein Therapeutics Association.
- Dr. Jerrold B. Grossman (Vice Chairman of the Board of Directors): A veteran leader heavily involved in the strategic oversight and long-term vision of the enterprise. He maintains close corporate ties, including shared service agreements providing vital real estate and infrastructure support to the firm.
- Brad Tade (Chief Financial Officer): The architect behind the modern financial strategy, balancing massive revenue growth with rigorous cost-control, tax strategies, and optimal debt syndication via the recent JPMorgan credit facility restructuring.
Subsidiaries, Associates, Joint Ventures
The enterprise exercises complete operational command through a 100% wholly owned subsidiary structure.
- ADMA BioManufacturing, LLC
- Ownership: 100%
- Contribution: Dominant segment generating 96.63% of total revenue. Handles all FDA-licensed fractionation, fill-finish, and therapeutic production.
- ADMA BioCenters Georgia Inc.
- Ownership: 100%
- Contribution: Operates the complex network of plasma collection centers. Generates 3.34% of total revenue via external plasma spot sales while feeding raw materials to BioManufacturing.
- ADMA Plasma Biologics, Inc.
- Ownership: 100%
- Contribution: Acts as an administrative and holding entity within the corporate architecture to facilitate structural efficiency.
Other Investments (Including Minority / Portfolio Holdings)
The enterprise operates a hyper-focused corporate structure. As of the current reporting period, there are no disclosed active minority holdings, portfolio investments, or passive equity investments measured at fair value outside of the core, wholly owned subsidiary framework.
Physical Properties
- Corporate Headquarters (Ramsey, NJ): Serving as the executive, administrative, and clinical coordination hub.
- Primary Manufacturing Campus (Boca Raton, FL): A massive, fully FDA-licensed plasma fractionation and purification facility. This 600,000-liter capacity plant handles end-to-end biological manufacturing, including in-house aseptic filling and final testing.
- Expansion Real Estate (Boca Raton, FL): Acquired in July 2025 for $12.6 million, this supplementary property ensures operational redundancies for ambient and critical cold-chain storage of highly sensitive raw plasma, work-in-process goods, and finished commercial inventory.
- ADMA BioCenters (Various U.S. Locations): A portfolio of ten active plasma collection facilities located predominantly in the southeastern United States, equipped with automated plasmapheresis technology.
Founders
Adam S. Grossman founded the enterprise in 2004. Recognizing a massive void in treatments for naturally and medically immunocompromised patients (such as those undergoing chemotherapy or solid organ transplants), he built the company to specifically engineer high-titer hyperimmune globulins. His early career as a hospital-based plasma products sales representative allowed him to directly observe the fatal consequences of respiratory infections in these vulnerable cohorts, acting as the catalyst for the firm’s creation.
Parent
The enterprise is a standalone, publicly traded corporation (Nasdaq: ADMA) and operates without a parent corporate entity.
Investments and Capital Expenditure Plans
Capital allocation is violently focused on capacity expansion, margin enhancement, and strategic pipeline acceleration.
- Yield Enhancement Rollout: Extensive capex was previously directed toward validating the yield enhancement production process. The 2025 FDA approval ensures this upfront investment will drive continuous, perpetual margin expansion.
- Pipeline – SG-001: Significant R&D and operational capital is actively deployed into the S. pneumoniae hyperimmune globulin program (SG-001). Following successful animal studies and a pilot-scale batch, the firm plans to submit a pre-IND package in 2026. An accepted Commissioner’s National Priority Voucher (CNPV) could accelerate FDA review by multiple quarters.
- Supply Chain Repositioning: Rather than deploying capex to build dozens of new collection centers, the firm opted for a capital-efficient supply model. By divesting three existing centers for $12.0 million and signing long-term raw plasma agreements with the buyer (and others like Grifols and KEDPlasma), the firm secured access to 280+ national collection centers, completely derisking supply constraints through the late 2030s.
Shareholding Pattern
- Total Shares Outstanding: 238,159,176 shares (as of Feb 20, 2026).
- Public/Non-Affiliate Holdings: 232,287,556 shares (approximately 97.5%).
- Promoters/Affiliates: Hold the remaining minority (~2.5%).
- Share Repurchase Action: In March 2026, the firm aggressively enhanced shareholder value by initiating a massive $125.0 million Accelerated Share Repurchase via JPMorgan, acting as the first tranche of a planned $200.0 million authorized initiative.
Future Strategy
The forward-looking strategy relies on aggressive commercial execution and label expansion.
- Financial Trajectory: Management has issued highly confident guidance, projecting total 2026 revenues to exceed $635.0 million (with Adjusted EBITDA surpassing $360.0 million), and looking out to 2029 with projections surpassing $1.1 billion in total revenue.
- Label Expansion: The firm is anticipating FDA approval in the first half of 2026 for an sBLA expanding ASCENIV’s label into the pediatric population (two years and older).
- Pipeline Penetration: The progression of SG-001 into a registrational clinical trial is expected to unlock a massive addressable market. S. pneumoniae is a predominant cause of community-acquired pneumonia, and this prophylactic/therapeutic hyperimmune globulin holds a peak annual revenue potential estimated at $300–$500 million.
Key Strengths
- Proprietary Immunotechnology: The patented microneutralization assay and specialized plasma pooling design create a virtually impenetrable moat around ASCENIV, allowing the reliable extraction of high-titer plasma found in less than 10% of donors.
- Margin Superiority: The implementation of the FDA-approved yield enhancement protocol extracts 20% more commercial product from identical raw material inputs, structurally guaranteeing best-in-class gross margins.
- Technological Integration: The deployment of “ADMAlytics” integrates artificial intelligence into the 7-to-12-month biological manufacturing cycle, optimizing plasma pools, slashing labor hours, and perfectly aligning inventory with commercial demand.
- Capital Efficiency: Broad long-term supply agreements with entities like Grifols and KEDPlasma guarantee access to raw material without the massive capital burden of owning hundreds of brick-and-mortar collection sites.
Key Challenges and Risks
- Extreme Regulatory Oversight: The FDA strictly governs all aspects of biologics. Any failure in cGMP compliance, adverse inspection outcomes, or safety issues could immediately result in warning letters, product recalls, or total suspension of manufacturing.
- Biological Manufacturing Complexities: Plasma fractionation is inherently volatile. A single batch takes 7 to 12 months to complete. Microbial contamination, viral inactivation failures, or out-of-specification test results can cause total lot loss.
- Customer Concentration: Historically, the enterprise relies heavily on a handful of massive distributors. In 2025, BioCare, Inc. and CuraScript SD Specialty Distribution accounted for a staggering 73% of total consolidated revenues.
- Medicaid Rebate Volatility: Accruals for U.S. Medicaid rebates represent highly complex estimates. Legislative changes (like the removal of the rebate cap or shifts in the 340B pricing program) could radically alter liability and erode net revenue.
Conclusion and Strategic Outlook
The organization has seamlessly transitioned from an ambitious clinical-stage biotech into an absolute powerhouse of commercial biologic manufacturing. By securing total vertical control over its supply chain, optimizing its production line with artificial intelligence, and achieving unprecedented 20% yield enhancements, the financial architecture is primed for explosive free cash flow generation. The strategic pivot to lock in long-term raw plasma supply agreements while minimizing physical real estate burdens ensures deep capital efficiency. Supported by an incredibly differentiated product in ASCENIV and a highly anticipated pipeline asset in SG-001, the enterprise is structurally positioned to comfortably breach the $1.1 billion annual revenue threshold by 2029 while commanding massive operating leverage.
FAQ
What is the core business of ADMA Biologics? The firm is an end-to-end commercial biopharmaceutical company that specializes in the collection, manufacturing, and marketing of plasma-derived therapeutics for immune-compromised patients.
What are the primary products sold by the company? The flagship products are ASCENIV and BIVIGAM (both Intravenous Immune Globulins for Primary Immunodeficiency Disease) and Nabi-HB (a hyperimmune globulin for Hepatitis B exposure).
How does ASCENIV differ from standard IVIG? ASCENIV utilizes a patented plasma donor screening and pooling process to ensure the final product contains high-titer neutralizing antibodies specifically targeted against respiratory syncytial virus (RSV) and other common pathogens.
What is the significance of the recent yield enhancement approval? In 2025, the FDA approved a novel manufacturing process that allows the company to extract approximately 20% more ASCENIV and BIVIGAM from the exact same starting volume of raw plasma, drastically increasing gross margins.
What is the SG-001 pipeline program? SG-001 is an investigative, pre-clinical hyperimmune globulin designed to combat S. pneumoniae infections. It holds an estimated peak annual revenue potential of $300 to $500 million.
How is artificial intelligence utilized in operations? The company utilizes a proprietary AI software known as “ADMAlytics” to predict supply chain outcomes, automate complex plasma pooling formulations, and streamline commercial distribution forecasting.
What is the 2026 financial outlook? Management projects total revenues exceeding $635.0 million, with Adjusted Net Income surpassing $255.0 million and Adjusted EBITDA breaching $360.0 million.
Official Site: https://www.admabiologics.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
